Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.54 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.50 |
| ▸ | DDT | P30046 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CD74 | P04233 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | FABP1 | P07148 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28267408 | 0.87 | PDE4A (0.62) | PDE4ASERPINE1BRD4PDE4CPDE4D | |
| SCHEMBL2952081 | 0.84 | FABP1 (0.60) | PDE4APDE4CPDE4DPDE4BKDR | |
| SCHEMBL418337 | 0.83 | SLC40A1 (0.57) | PDE4ASERPINE1BRD4PDE4CPDE4D | |
| SCHEMBL13169354 | 0.81 | MEN1 (0.53) | PDE4ASERPINE1PDE4CPDE4DPDE4B | |
| SCHEMBL16502608 | 0.79 | SLC40A1 (0.50) | PDE4APDE4CPDE4DKDRLMNA | |
| SCHEMBL22282149 | 0.79 | MEN1 (0.48) | PDE4ASERPINE1BRD4PDE4CPDE4D | |
| SCHEMBL17174193 | 0.78 | PDE4A (0.49) | PDE4AKMOPDE4CPDE4DPDE4B | |
| SCHEMBL22816701 | 0.78 | L3MBTL1 (0.64) | PDE4AKMOPDE4CPDE4DLMNA | |
| SCHEMBL4148271 | 0.78 | MMP2 (0.60) | PDE4ABRD4LMNAMETAP2METAP1 | |
| SCHEMBL19009568 | 0.78 | BRD4 (0.53) | PDE4ASERPINE1BRD4KDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-102378753-B | Plasminogen activator-1 inhibitor | RENASCIENCE Co.,Ltd. (JP) | 2016-03-02 | — | — | CN | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| CN-102378753-A | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO LTD | 2012-03-14 | — | — | CN | disclosed |
| EP-2415755-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Renascience CO., LTD. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-5968985-A | INHIBITORS OF SODIUM ION/HYDROGEN ION EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| EP-0773927-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996004241-A2 | BENZOYLGUANIDINE DERIVATIVES AS MEDICAMENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | PDE4A 2445/4885SERPINE1 1/4885KMO 2924/4885 |
| US-20120022080-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | PDE4A 2445/4885SERPINE1 1/4885KMO 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.